Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,095 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: B cell infusion Clear all

Conditions: SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Interventions: Alemtuzumab 0.3 mg, Cyclophosphamide, Busulfan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Melphalan, Alemtuzumab 0.2 mg, Fludarabine phosphate 30 mg, MESNA; Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 50 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Myeloma
Interventions: hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions: MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more

Conditions: Diffuse B-Cell Lymphoma
Interventions: Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion, Vincristine, Prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • St Louis, Missouri

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
Interventions: AEG35156 antisense IV infusion; Drug
Lead sponsor: Aegera Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Burbank, California • Valhalla, New York • Cleveland, Ohio + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: Epratuzumab; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 11 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ublituximab, Umbralisib, Venetoclax; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 50
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more

Conditions: Relapsed Adult AML, Refractory AML, Acute Myelogenous Leukemia
Interventions: AdaptNK, Fludarabine, Cyclophosphamide, IL-2; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Interventions: Bevacizumab, Carboplatin, Paclitaxel, AG-013736 (axitinib); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 22
States / cities: Baton Rouge, Louisiana • Pittsfield, Massachusetts • Columbus, Mississippi + 14 more

Conditions: Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions: denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 34
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Calaspargase pegol (S95015); Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 22 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Leukemia
Interventions: Nelarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma, Hodgkin Lymphoma (Category), Nodular Lymphocyte Predominant Hodgkin Lymphoma
Interventions: Rituximab; Drug
Lead sponsor: Ranjana Advani; Other
Eligibility: 3 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 2
States / cities: Stanford, California

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced or Metastatic Solid Tumors
Interventions: TAK-188; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 15
States / cities: Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more

Conditions: Relapsed or Refractory Large B-cell Lymphoma
Interventions: KITE-753, Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 21
States / cities: Goodyear, Arizona • Duarte, California • Stanford, California + 16 more

Conditions: Cancer
Interventions: LY2801653, Cetuximab, Cisplatin, Gemcitabine, Ramucirumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • New York, New York + 2 more

Conditions: Diabetes Mellitus, Ischemic Heart Disease
Interventions: 100 million Allogeneic Mesenchymal Human Stem Cells, Placebo; Drug · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab, Boserolimab, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), HER3-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 18
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more

Conditions: NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Anchorage, Alaska • Fort Lauderdale, Florida • Plantation, Florida

Conditions: Lymphoma
Interventions: Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI), Allogeneic bone marrow transplantation, Cyclosporin (CSA), Mycophenolate mofetil (MMF), Methotrexate (MTX); Procedure · Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 19
States / cities: Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 12 more

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Interventions: MK-1045; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Los Angeles, California • Denver, Colorado • Cleveland, Ohio + 1 more

Conditions: SCID
Interventions: Busulfan, Cell processing for TCRαβ+/CD19+ depletion; Drug · Device
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 0 Years to 2 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more

Conditions: Non-hodgkin Lymphoma
Interventions: Venetoclax; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Rituximab in Treating Patients With Hodgkin's Lymphoma

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

A Study of LY2801653 in Advanced Cancer

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Conditioning SCID Infants Diagnosed Early

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma